In its investor call on Thursday, Coherus Biosciences revealed that it will launch its biosimilar pegfilgrastim, Udenyca, at a 33% discount to the reference Neulasta.
In its investor call on Thursday, Coherus Biosciences revealed that it will launch its biosimilar pegfilgrastim, Udenyca, at a 33% discount to the reference Neulasta. The drug’s launch is slated for January 3, 2019. Udenyca’s list price of $4175 per unit matches Mylan’s price for its biosimilar pegfilgrastim, Fulphila, which launched in the United States in July 2018.
Prior to Coherus’ announcement of its price for its product, Mylan was the only the second biosimilar developer to offer a discount deeper than 30% in the US market; Samsung Bioepis’ infliximab biosimilar, Renflexis, launched at a 35% discount to its reference, but other products, such as Celltrion’s Inflectra and Sandoz’s Zarxio, launched at discounts of just 15%.
Despite the fact that Coherus has matched Mylan on list price for the pegfilgrastim product, these prices do not take into consideration additional rebates and discounts that the drug makers may offer as a means to differentiate their products in the marketplace.
Coherus also noted in its investor call that it has finished hiring approximately 70 sales representatives, covering 7 US regions, to support sales of Udenyca. The company also recently launched a comprehensive website for its provider services, reimbursement support, and patient co-pay assistance program.
Looking to the future, Coherus reported that it plans to file a Biologics License Application for its adalimumab biosimilar referencing Humira, CHS-1420, before the end of 2019. It is also working on 2 biosimilars targeting eye diseases: CHS-3351 (a ranibizumab biosimilar referencing Lucentis) and CHS-2020 (an aflibercept biosimilar referencing Eylea).
Notably, the company, which has thus far focused on biosimilars, also reports that it plans to initiate a phase 2 clinical trial of an innovator small-molecule drug. CHS-131 is a candidate drug for the treatment of nonalcoholic steatohepatitis, or NASH.
The diversification into innovator drug development has also been the strategy of other biosimilar developers in recent months; Samsung Bioepis has announced that it is in a phase 1 clinical trial with SB26, an novel ulinastatin-Fc fusion protein, and Celltrion has expanded its pipeline to include innovator biologics for the treatment breast cancer, hepatitis B virus, and rabies.
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements
February 25th 2025The FDA and European Medicines Agency (EMA) mandate high similarity between biosimilars and reference products, but their regulatory processes differ, especially with multiple reference products.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Similar Survival, Safety for Bevacizumab Biosimilar vs Originator in Colorectal Cancer
February 8th 2025A retrospective observational study found no significant differences in progression-free survival or safety in patients with colorectal cancers in Japan treated with ABP 215, Amgen’s bevacizumab biosimilar, or reference bevacizumab (Avastin), and estimated cost savings of 800,000 Japanese yen (approximately $5100) per patient with the biosimilar.